BriaCell Therapeutics Corp. announced continued outstanding topline survival and clinical benefit data in advanced metastatic breast cancer patients treated Bria-IMT in combination with an immune check point inhibitor (CPI). The data is being revealed at the 2023 San Antonio Breast Cancer Symposium®?

held at Henry B. Gonzalez Convention Center, San Antonio, TX. Phase 2 Combination Study of Bria-IMT?? with Immune Check Point Inhibitor: The Phase 2 study is fully enrolled.

An aggregate of 54 advanced metastatic breast cancer patients have been enrolled in the study {11 patients with KEYTRUDA®? (pembrolizumab), and 43 patients with Incyte's retifanlimab with one patient cross over from the KEYTRUDA®? study to retifanlimab study.

Data is available on 48 of these heavily pre-treated metastatic breast cancer patients (average number of prior treatments = 6). Excellent Overall Survival and Tolerability: Interim analysis using Kaplan-Meier curve method, measuring the probability of patients' survival in time, showed median overall survival (OS) of 13.4 months for 54 patients. This is a marked improvement over the benchmark 6.7-9.8 months reported in similar (third line or higher) patients.

32 out of 42 patients that have received treatment since 2022 remain alive, suggesting tolerability and survival efficacy. The data will continue to mature as patients remain on the study. All patients were able to receive therapy with no toxicity related discontinuations.